Through a statement prepared by the Parkinsonís Action Network (PAN), The Michael J. Fox Foundation, PAN and other Parkinsonís organizations applaud efforts to develop new Parkinsonís disease (PD) drugs, but call for more research to find medications that slow or halt the disease process.
The statement is in response to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) stating that 37 PD drugs are in the clinical development pipeline. All 37 were developed by either U.S.-based companies or foreign companies conducting clinical trials in the U.S. There are many other medications and therapies for PD being developed outside the U.S.
ďWe are pleased to see that there are 37 new drugs making their way to patients,Ē said Amy Comstock Rick, CEO of the PAN. ďHowever, the number of new drugs is not as important as whether these medications are ultimately effective in improving the quality of life for people with Parkinsonís. As a community, we will continue to fight to ensure that researchers have the funds and resources they need to bring us closer to drugs or therapies that directly slow or halt the progression of this disease.Ē
Read more of the PD organizations' statement.
Visit the PhRMA site to read the full report.